Quick Answer
Theravance Biopharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $167.81 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +344.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $167.81 million | Fiscal year 2024: $37.80 million | Fiscal year 2023: $39.55 million | Fiscal year 2022: $298.17 million | Fiscal year 2021: $89.96 million | Fiscal year 2020: $81.47 million | Fiscal year 2019: $58.06 million | Fiscal year 2018: $378.02 million | Fiscal year 2017: $88.98 million | Fiscal year 2016: $344.71 million | Fiscal year 2015: $112.71 million | Fiscal year 2014: $89.22 million | Fiscal year 2014: $277.54 million | Fiscal year 2013: $0.00 | Fiscal year 2012: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: